Harmala Alkaloids and Other Compounds in Traditional Preparations
Harmine and harmaline (the MAOI part of ayahuasca), LSA in morning glory-type seeds and bufotenine are different compounds. Each is described by its source, evidence, risks and legal listing.
Content last updated . This page has not been medically reviewed.
Documented analytical data
Each group below is one study's measurement of the stated specimen or preparation. It is not a typical value for the species or product, varies between specimens, and says nothing about effects or safety. 53 values from 5 sources.
Jiang N, Chen L, Li J, Li W, Jiang S. Lethal and Sublethal Toxicity of Beta-Carboline Alkaloids from Peganum harmala... (4 values)
Source: Jiang N, Chen L, Li J, Li W, Jiang S. Lethal and Sublethal Toxicity of Beta-Carboline Alkaloids from Peganum harmala (L.) against Aedes albopictus Larvae. Toxics 2023;11:341. DOI 10.3390/toxics11040341. Read 2026-10-22. Laboratory: Key Laboratory of Environmental Medicine Engineering, Southeast University, Nanjing, China. Method: isolation by column fractionation; compounds identified by HPLC and ESI-MS; quantitation method not clearly stated in the text read. Date: seeds collected August 2020.
| Specimen or preparation | Analyte | Value | What it is | Sample size and scope |
|---|---|---|---|---|
| Peganum harmala L. seeds, fresh seeds collected August 2020, Huan County, northwest China, dried to constant weight at 60 C | harmaline | 2.62 % w/w (dry weight of seeds) | (reported) | not stated. single batch (1 kg of seeds processed) |
| Peganum harmala L. seeds, fresh seeds collected August 2020, Huan County, northwest China, dried to constant weight at 60 C | harmalol | 0.32 % w/w (dry weight of seeds) | (reported) | not stated. single batch (1 kg of seeds processed) |
| Peganum harmala L. seeds, fresh seeds collected August 2020, Huan County, northwest China, dried to constant weight at 60 C | harman | 0.15 % w/w (dry weight of seeds) | (reported) | not stated. single batch (1 kg of seeds processed) |
| Peganum harmala L. seeds, fresh seeds collected August 2020, Huan County, northwest China, dried to constant weight at 60 C | harmine | 1.59 % w/w (dry weight of seeds) | (reported) | not stated. single batch (1 kg of seeds processed) |
Rodriguez L, Lopez A, Moyna G, Seoane GA, Davyt D, Vazquez A, Hernandez G, Carrera I (2022) New Insights into the Che... (30 values)
Source: Rodriguez L, Lopez A, Moyna G, Seoane GA, Davyt D, Vazquez A, Hernandez G, Carrera I (2022) New Insights into the Chemical Composition of Ayahuasca. ACS Omega 7(14):12307-12317, doi 10.1021/acsomega.2c00795. Read 2026-10-22. Laboratory: Universidad de la Republica (Departamento de Quimica Organica and related units), Montevideo, Uruguay. Method: qNMR (PULCON approach, 400 MHz) after ethyl acetate extraction; alkaloid identity also checked by LC-MS/MS. Date: not reported in source.
| Specimen or preparation | Analyte | Value | What it is | Sample size and scope |
|---|---|---|---|---|
| Ayahuasca sample N1 (neoshamanic setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | DMT | 0.532 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample N1 (neoshamanic setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | harmaline | 0.132 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample N1 (neoshamanic setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | harmine | 3.27 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample N1 (neoshamanic setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | harmol | 0.103 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample N1 (neoshamanic setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | tetrahydroharmine (THH) | 1.1 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample N2 (neoshamanic setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | DMT | 0.607 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample N2 (neoshamanic setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | harmaline | 0.234 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample N2 (neoshamanic setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | harmine | 2.97 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample N2 (neoshamanic setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | harmol | 0.094 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample N2 (neoshamanic setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | tetrahydroharmine (THH) | 1.53 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample R1 (religious setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | DMT | 1.86 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample R1 (religious setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | harmaline | 0.241 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample R1 (religious setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | harmine | 1.65 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample R1 (religious setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | harmol | 0.073 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample R1 (religious setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | tetrahydroharmine (THH) | 1.44 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample R2 (religious setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | DMT | 1.04 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample R2 (religious setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | harmaline | 0.213 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample R2 (religious setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | harmine | 1.34 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample R2 (religious setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | harmol | 0.09 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample R2 (religious setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | tetrahydroharmine (THH) | 1.11 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample R3 (religious setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | DMT | 1.32 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample R3 (religious setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | harmaline | 0.161 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample R3 (religious setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | harmine | 1.56 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample R3 (religious setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | harmol | 0.047 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample R3 (religious setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | tetrahydroharmine (THH) | 1.03 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample T1 (therapeutic setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | DMT | 1.82 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample T1 (therapeutic setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | harmaline | 0.452 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample T1 (therapeutic setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | harmine | 5.61 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample T1 (therapeutic setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | harmol | 0.29 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
| Ayahuasca sample T1 (therapeutic setting), donated by a user group in Uruguay; liquid brew, results per gram of brew (viscosity prevented volumetric measurement) | tetrahydroharmine (THH) | 2.33 mg/g (brew mass (mg per g of ayahuasca)) | (reported) | 1. single preparation (mean of 3 extractions of one sample) |
Santos MC, Navickiene S, Gaujac A (2017) Determination of Tryptamines and beta-Carbolines in Ayahuasca Beverage Consu... (2 values)
Source: Santos MC, Navickiene S, Gaujac A (2017) Determination of Tryptamines and beta-Carbolines in Ayahuasca Beverage Consumed During Brazilian Religious Ceremonies. J AOAC Int, PMID 28105971. Abstract read via Europe PMC 2026-10-22 (full text not read). Laboratory: not reported in abstract read (authors: Santos, Navickiene, Gaujac). Method: SPE followed by LC with UV diode-array detection (LOD 0.12 mg/L). Date: not reported in source.
| Specimen or preparation | Analyte | Value | What it is | Sample size and scope |
|---|---|---|---|---|
| Ayahuasca samples from one religious group's cooking process, Fortaleza, Ceara, Brazil | tryptamines and beta-carbolines (DMT, tryptamine, harmine, harmaline, harmalol, THH): maximum concentration over all target compounds as stated in abs | 36.7 g/L (brew volume (unit as written in source abstract)) | (reported) | 20. range across N specimens: the abstract gives one combined range for the target compounds; per-compound values not read |
| Ayahuasca samples from one religious group's cooking process, Fortaleza, Ceara, Brazil | tryptamines and beta-carbolines (DMT, tryptamine, harmine, harmaline, harmalol, THH): minimum concentration over all target compounds as stated in abs | 0.3 g/L (brew volume (unit as written in source abstract)) | (reported) | 20. range across N specimens: the abstract gives one combined range for the target compounds; per-compound values not read |
Santos BWL, de Oliveira RC, Sonsin-Oliveira J, Fagg CW, Barbosa JBF, Caldas ED (2020) Biodiversity of beta-Carboline... (12 values)
Source: Santos BWL, de Oliveira RC, Sonsin-Oliveira J, Fagg CW, Barbosa JBF, Caldas ED (2020) Biodiversity of beta-Carboline Profile of Banisteriopsis caapi and Ayahuasca, a Plant and a Brew with Neuropharmacological Potential. Plants (Basel) 9(7):870, doi 10.3390/plants9070870. Read 2026-10-22. Laboratory: Laboratory of Toxicology, Department of Pharmacy, University of Brasilia, Brazil. Method: LC-ESI-MS/MS (Shimadzu LC, AB Sciex 4000 Qtrap, MRM), brew diluted 750-fold. Date: Brews prepared 2017 to 2020 (liana samples 2016 to 2019); exact analysis dates not reported in source.
| Specimen or preparation | Analyte | Value | What it is | Sample size and scope |
|---|---|---|---|---|
| Ayahuasca brews (finished beverage, frozen at -20 C until analysis) supplied by UDV (5), ICEFLU (1) and groups referred to as Daime (27), prepared 2017-2020 in Acre, Goias and the Federal District, Brazil | DMT (maximum) | 3.12 mg/mL (brew volume) | (reported) | 32. dataset (N=32): highest value among the brews. One brew made only with B. caapi (no DMT) excluded. |
| Ayahuasca brews (finished beverage, frozen at -20 C until analysis) supplied by UDV (5), ICEFLU (1) and groups referred to as Daime (27), prepared 2017-2020 in Acre, Goias and the Federal District, Brazil | DMT (mean) | 1.08 mg/mL (brew volume) | (reported) | 32. dataset (N=32): arithmetic mean across the brews. One brew made only with B. caapi (no DMT) excluded. |
| Ayahuasca brews (finished beverage, frozen at -20 C until analysis) supplied by UDV (5), ICEFLU (1) and groups referred to as Daime (27), prepared 2017-2020 in Acre, Goias and the Federal District, Brazil | DMT (minimum) | 0.1 mg/mL (brew volume) | (reported) | 32. dataset (N=32): lowest value among the brews. One brew made only with B. caapi (no DMT) excluded. |
| Ayahuasca brews (finished beverage, frozen at -20 C until analysis) supplied by UDV (5), ICEFLU (1) and groups referred to as Daime (27), prepared 2017-2020 in Acre, Goias and the Federal District, Brazil | harmaline (maximum) | 0.945 mg/mL (brew volume) | (reported) | 33. dataset (N=33): highest value among the brews. |
| Ayahuasca brews (finished beverage, frozen at -20 C until analysis) supplied by UDV (5), ICEFLU (1) and groups referred to as Daime (27), prepared 2017-2020 in Acre, Goias and the Federal District, Brazil | harmaline (mean) | 0.195 mg/mL (brew volume) | (reported) | 33. dataset (N=33): arithmetic mean across the brews. |
| Ayahuasca brews (finished beverage, frozen at -20 C until analysis) supplied by UDV (5), ICEFLU (1) and groups referred to as Daime (27), prepared 2017-2020 in Acre, Goias and the Federal District, Brazil | harmaline (minimum) | 0.012 mg/mL (brew volume) | (reported) | 33. dataset (N=33): lowest value among the brews. |
| Ayahuasca brews (finished beverage, frozen at -20 C until analysis) supplied by UDV (5), ICEFLU (1) and groups referred to as Daime (27), prepared 2017-2020 in Acre, Goias and the Federal District, Brazil | harmine (maximum) | 7.11 mg/mL (brew volume) | (reported) | 33. dataset (N=33): highest value among the brews. |
| Ayahuasca brews (finished beverage, frozen at -20 C until analysis) supplied by UDV (5), ICEFLU (1) and groups referred to as Daime (27), prepared 2017-2020 in Acre, Goias and the Federal District, Brazil | harmine (mean) | 1.28 mg/mL (brew volume) | (reported) | 33. dataset (N=33): arithmetic mean across the brews. |
| Ayahuasca brews (finished beverage, frozen at -20 C until analysis) supplied by UDV (5), ICEFLU (1) and groups referred to as Daime (27), prepared 2017-2020 in Acre, Goias and the Federal District, Brazil | harmine (minimum) | 0.109 mg/mL (brew volume) | (reported) | 33. dataset (N=33): lowest value among the brews. |
| Ayahuasca brews (finished beverage, frozen at -20 C until analysis) supplied by UDV (5), ICEFLU (1) and groups referred to as Daime (27), prepared 2017-2020 in Acre, Goias and the Federal District, Brazil | tetrahydroharmine (THH) (maximum) | 3.05 mg/mL (brew volume) | (reported) | 33. dataset (N=33): highest value among the brews. |
| Ayahuasca brews (finished beverage, frozen at -20 C until analysis) supplied by UDV (5), ICEFLU (1) and groups referred to as Daime (27), prepared 2017-2020 in Acre, Goias and the Federal District, Brazil | tetrahydroharmine (THH) (mean) | 1.16 mg/mL (brew volume) | (reported) | 33. dataset (N=33): arithmetic mean across the brews. |
| Ayahuasca brews (finished beverage, frozen at -20 C until analysis) supplied by UDV (5), ICEFLU (1) and groups referred to as Daime (27), prepared 2017-2020 in Acre, Goias and the Federal District, Brazil | tetrahydroharmine (THH) (minimum) | 0.09 mg/mL (brew volume) | (reported) | 33. dataset (N=33): lowest value among the brews. |
Wang N, An J, Zhang Z, Liu Y, Fang J, Yang Z. The Antimicrobial Activity and Characterization of Bioactive Compounds... (5 values)
Source: Wang N, An J, Zhang Z, Liu Y, Fang J, Yang Z. The Antimicrobial Activity and Characterization of Bioactive Compounds in Peganum harmala L. Based on HPLC and HS-SPME-GC-MS. Front Microbiol 2022;13:916371. DOI 10.3389/fmicb.2022.916371. Read 2026-10-22. Laboratory: School of Pharmacy, Lanzhou University, Lanzhou, China. Method: varies by row (see source). Date: varies by row.
| Specimen or preparation | Analyte | Value | What it is | Sample size and scope |
|---|---|---|---|---|
| Peganum harmala L. aerial parts (4 samples H1-H4; from Pakistan and Gansu, China) | harmaline and harmine | 0 not detected (aerial parts) | (reported) | 4. 4 samples; neither alkaloid detected |
| Peganum harmala L. seeds (6 samples S1-S6, dried seeds collected from Xinjiang, China) | harmaline | 88.05 ug/g (as reported (ug per g of powdered plant material; moisture not stated) - lowest of range) | (reported) | 6. range across 6 seed samples (values given as a range only) |
| Peganum harmala L. seeds (6 samples S1-S6, dried seeds collected from Xinjiang, China) | harmaline | 472.23 ug/g (as reported (ug per g of powdered plant material; moisture not stated) - highest of range) | (reported) | 6. range across 6 seed samples (values given as a range only) |
| Peganum harmala L. seeds (6 samples S1-S6, dried seeds collected from Xinjiang, China) | harmine | 136.41 ug/g (as reported (ug per g of powdered plant material; moisture not stated) - lowest of range) | (reported) | 6. range across 6 seed samples (values given as a range only) |
| Peganum harmala L. seeds (6 samples S1-S6, dried seeds collected from Xinjiang, China) | harmine | 650.12 ug/g (as reported (ug per g of powdered plant material; moisture not stated) - highest of range) | (reported) | 6. range across 6 seed samples (values given as a range only) |
Interaction and poisoning warning first. Harmala alkaloids block an enzyme called monoamine oxidase (MAO). A 2026 case report describes a man who developed severe serotonin syndrome with respiratory failure, needing a breathing tube and intensive care, after ayahuasca followed by over-the-counter dextromethorphan and diphenhydramine. He recovered. [1] Poisoning with a different harmala-containing plant, Syrian rue, has also caused unconsciousness, high blood pressure and a fast heartbeat. [2] If anyone has severe agitation, fever, muscle rigidity, seizures, confusion or trouble breathing after taking any of these, call 911 (US) or US Poison Help at 1-800-222-1222. See poisoning: what to do first. Never stop or change prescribed medicines on your own; talk with the prescriber. This page gives no amounts, preparation or use instructions, and does not help identify plants.
Evidence labels used here: preclinical (cells or animals only), insufficient evidence, evidence of harm, marketing claim. Where we looked and found nothing usable, we write "Proper evidence not found." Each compound below has a different source and action; none stands in for another.
Harmine and harmaline
What they are. Harmine, harmaline and tetrahydroharmine are β-carboline alkaloids found in the ayahuasca vine Banisteriopsis caapi, and the vine has monoamine oxidase inhibitory activity. [3] A review describes β-carbolines as a prominent class of MAO-A inhibitors. [4] The same alkaloids are named in Peganum harmala (Syrian rue), a different plant. [2] Plant names checked in GBIF. [5]Role in ayahuasca. Ayahuasca is made from two kinds of plants: one rich in DMT, usually Psychotria viridis, and one supplying β-carbolines such as harmine, from the B. caapi vine. [6] MAO-A has the primary role in DMT metabolism. [7] In a single-blind study of 16 healthy volunteers using an ayahuasca-inspired DMT and harmine formulation (not a traditional preparation, and with some authors affiliated with companies), harmine reduced the metabolism of DMT and the authors reported a favorable safety profile. [8] That shows harmine changes how the body handles DMT; it is not a safety guarantee. DMT and ayahuasca are separate topics: see DMT, ayahuasca and Ayahuasca vine.
Research on the isolated alkaloids.
- Depression and anxiety: preclinical. A systematic review found animal studies showing anxiolytic and antidepressive effects of ayahuasca, harmine and harmaline. The human studies it describes involved ayahuasca itself, not isolated alkaloids. [9]
- Parkinson's-type movement: preclinical. In a marmoset model, B. caapi extract and harmine gave mild improvement in motor disability. [3]
- Alzheimer's disease: preclinical. A 2026 review describes accumulating preclinical evidence. [10]
- Human use of isolated harmine as a treatment: insufficient evidence. Proper evidence not found for a clinical efficacy trial in the sources we checked.
Toxicity. A systematic review of 78 articles found ayahuasca or DMT generally safe in controlled settings but with some adverse events. Animal studies at higher doses showed abortifacient and teratogenic effects, and harmaline revealed the most issues in preclinical models. The authors warn animal results may not apply to people. [11] Pregnancy: Proper evidence not found in people; see pregnancy and breastfeeding.
LSA (lysergic acid amide) in seeds
LSA is primarily consumed through preparations from the seeds of Convolvulaceae (morning glory family) plants. A 2025 systematic review of 17 human studies reported euphoria, hallucinations, nausea and anxiety, and documented severe outcomes including psychosis, hypertension and hospitalization. It notes some evidence suggesting possible use for cluster headaches, variable dosing and online misinformation, and concludes LSA poses significant health risks with little scientific study. [12] Label for any benefit: insufficient evidence.A study of online user reports and medical case reports found recreational use of Ipomoea tricolor and I. violacea seeds had reappeared, with suicidal ideation in two users and frequent combination with other drugs. [13] Those are user and case reports, not controlled studies.
Ololiuqui is the Aztec name for seeds of Turbina corymbosa (now treated as a synonym of Ipomoea corymbosa in GBIF). A Mesoamerica review says they contain lysergic acid amide and were used by Olmec, Zapotec, Maya and Aztec peoples. [14][5] This site does not describe ceremonies. See Indigenous traditions, ethics and conservation and morning glory and other documented plants.
Bufotenine
Bufotenine (5-hydroxy-N,N-dimethyltryptamine) is a tryptamine. [15] A review of the tree Anadenanthera colubrina says bufotenine was isolated from its seeds and is related to hallucinogenic activity; it says bufotenine could make the seeds toxic, though toxicity was not found in assays of seed extracts. Most medicinal claims for that tree rest on lab and animal tests. [16] A 2025 narrative review also lists bufotenine among animal-derived toxins. [17] A Mesoamerica review says toad skin contains bufotoxins with hallucinogenic properties and was used from the Olmec period. [14] This page does not describe collection or use of any animal. Bufotenine is not 5-MeO-DMT: the US Schedule I list names them as separate entries. [15] 5-MeO-DMT has its own guide: 5-MeO-DMT. Proper evidence not found for human clinical trials of bufotenine.Regulatory status (not legal advice; laws change)
- US federal, read 2026-10-22: bufotenine is named in the Schedule I list in 21 CFR 1308.11. [15] Lysergic acid and lysergic acid amide are named in the Schedule III list in 21 CFR 1308.13. [18] We did not find harmine or harmaline named in either list.
- United Kingdom, read 2026-10-22: Schedule 2, Part I (Class A) of the Misuse of Drugs Act 1971 names bufotenine and lysergamide. We did not find harmine or harmaline named. [19] We did not check what products or plants that covers.
- Plants and seeds: how law treats the plants (B. caapi, P. harmala, morning glory seeds) was not verified. Other countries and US states: not verified. See legal status by country.
Frequently asked questions
Are harmine and harmaline psychedelics?
They are described as MAO inhibitors in the ayahuasca vine, not as the serotonin-acting DMT. [6][3]
Why do MAO inhibitors matter for medicines?
In ayahuasca they can predispose people to serotonin toxicity when combined with serotonin-affecting agents. [1]
Is LSA the same as LSD?
No. A 2025 review calls LSA an LSD analog, meaning a related but distinct substance, and documents its own risks. [12]
Is bufotenine the same as 5-MeO-DMT?
No. The US Schedule I list names them as separate entries; see the separate 5-MeO-DMT guide. [15]
Is any of this approved as a medicine?
We found no regulator approval for these compounds in the sources we read.
References
- Pack S et al. Severe Serotonin Syndrome With Acute Respiratory Failure Following Ayahuasca and Dextromethorphan Use: A Case Report. Cureus. 2026 Aug 9;18(8):e114211. Read 2026-10-22 (abstract on PubMed).
- Yuruktumen A et al. Syrian rue tea: a recipe for disaster. Clin Toxicol (Phila). 2008 Sep;46(8):749-52. Read 2026-10-22 (abstract on PubMed).
- Fisher R et al. The effect of Banisteriopsis caapi (B. caapi) on the motor deficits in the MPTP-treated common marmoset model of Parkinson's disease. Phytother Res. 2018 Apr;32(4):678-687. Read 2026-10-22 (abstract on PubMed).
- Benny F et al. Review of β-carboline and its derivatives as selective MAO-A inhibitors. Arch Pharm (Weinheim). 2023 Jul;356(7):e2300091. Read 2026-10-22 (abstract on PubMed).
- Global Biodiversity Information Facility, GBIF species match, checked for the plant and fungus names on this page. Read 2026-10-22.
- Dos Santos RG et al. Ayahuasca: pharmacology, safety, and therapeutic effects. CNS Spectr. 2024 Nov 20;30(1):e2. Read 2026-10-22 (abstract on PubMed).
- Eckernäs E et al. N, N-dimethyltryptamine forms oxygenated metabolites via CYP2D6 - an in vitro investigation. Xenobiotica. 2023 Dec;53(8-9):515-522. Read 2026-10-22 (abstract on PubMed).
- Egger K et al. Examining the pharmacokinetic and pharmacodynamic interaction of N,N-dimethyltryptamine and harmine in healthy volunteers: Α factorial dose-escalation study. Biomed Pharmacother. 2025 Mar;184:117908. Read 2026-10-22 (abstract on PubMed).
- Dos Santos RG et al. Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies. Braz J Psychiatry. 2016 Mar;38(1):65-72. Read 2026-10-22 (abstract on PubMed).
- Shen X et al. Harmine and its derivatives: A promising multi-target therapeutic avenue for Alzheimer's disease. Neuroscience. 2026 May 7;601:155-168. Read 2026-10-22 (abstract on PubMed).
- White E et al. Ayahuasca and Dimethyltryptamine Adverse Events and Toxicity Analysis: A Systematic Thematic Review. Int J Toxicol. 2024 May-Jun;43(3):327-339. Read 2026-10-22 (abstract on PubMed).
- Lysergic Acid Amide (LSA), an LSD Analog: Systematic Review of Pharmacological Effects, Adverse Outcomes, and Therapeutic Potentials. Pharmacy (Basel). 2025 Jul 21;13(4):98. Read 2026-10-22 (abstract on PubMed).
- Juszczak GR et al. Recreational use of D-lysergamide from the seeds of Argyreia nervosa, Ipomoea tricolor, Ipomoea violacea, and Ipomoea purpurea in Poland. J Psychoactive Drugs. 2013 Jan-Mar;45(1):79-93. Read 2026-10-22 (abstract on PubMed).
- Hallucinogenic drugs in pre-Columbian Mesoamerican cultures. Neurologia. 2015 Jan-Feb;30(1):42-9. Read 2026-10-22 (abstract on PubMed).
- US Electronic Code of Federal Regulations, 21 CFR 1308.11 Schedule I. Read 2026-10-22.
- Delices M et al. Anadenanthera colubrina (Vell) Brenan: Ethnobotanical, phytochemical, pharmacological and toxicological aspects. J Ethnopharmacol. 2023 Jan 10;300:115745. Read 2026-10-22 (abstract on PubMed).
- Ciszowski K et al. Natural hallucinogens of fungal and animal origin: action and potentialapplications - a narrative review. Folia Med Cracov. 2025 Jul 31;65(2):5-18. Read 2026-10-22 (abstract on PubMed).
- US Electronic Code of Federal Regulations, 21 CFR 1308.13 Schedule III. Read 2026-10-22.
- UK Parliament, legislation.gov.uk, Misuse of Drugs Act 1971, Schedule 2. Read 2026-10-22.